SEATTLE & VANCOUVER, British Columbia–(BUSINESS WIRE)–Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal”) and SōRSE Technology Corporation (“SōRSE”) have entered into a Collaborative Research Agreement to advance Pascal’s PAS-393 into clinical testing. Pascal and SōRSE will share their respective technologies to test the cannabinoid PAS-393 in human volunteers, enabling testing of cancer patients treated with checkpoint inhibitors. As initially announced last March, this partnership leverages SōRS

READ MORE: https://www.businesswire.com/news/home/20200915005095/en/Biotech-Company-Pascal-Biosciences-and-S%C5%8DRSE-Technology-Announce-Partnership-for-Cannabinoid-Drug-Development-and-Cancer-Clinical-Trials/?feedref=JjAwJuNHiystnCoBq_hl-W8j9Oi60kFTomUxRDB8jhB8bDel5XZmwWFQYQPHxx__rCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3kCXJZE-1b1nXn968wYfofVLkaZDLiczsahzEklD3R10Q==